Immutep (ASX:IMM) has announced that the investigator-initiated EFTISARC-NEO Phase 2 trial evaluating its eftilagimod alpha with radiotherapy plus MSD's KEYTRUDA (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint. …
Immutep’s efti combination meets primary endpoint in Phase 2 soft tissue sarcoma
May 26, 2025 Australian Biotech
Latest Video
New Stories
-
Australian company secures FDA approval to progress development of CAR-T therapy
June 16, 2025 - - Latest News -
These systems are and always have been more similar than most realise
June 16, 2025 - - Latest News -
Confirmation the UK has agreed to review medicine prices in response to US demand
June 16, 2025 - - Latest News -
Amplia says pathological complete response in patient from ACCENT trial
June 16, 2025 - - Australian Biotech -
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 - - Latest News -
'There is a very real impact on Australian patients and clinicians'
June 15, 2025 - - Latest News -
Why not construct an off-ramp based on what you were going to do anyway?
June 15, 2025 - - Latest News